TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04325828

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apalutamide
Description: Apalutamide 240 mg (4\*60-mg tablets) will be administered orally once daily with or without food.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH Agonist
Description: A stable regimen of goserelin 3.6 mg will be administered as a GnRH agonist.
Study: NCT01647737

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Xylitol
Description: 4-6 times daily
Study: NCT06321692

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of blood levels of biomarkers of cardiac damage
Description: Evaluation of ultra-sensitive troponin I, BNP, NT-proBNP, and ST2 in patients with diagnosed neuroendocrine tumours (NET) with or without carcinoid syndrome
Study: NCT02153502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)
Description: AVP-786 capsules administered twice a day over a 10-week period

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules administered twice a day over a 10-week period
Study: NCT00977847

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Portals for collecting Family History data
Description: Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
Study: NCT01900002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT00977847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Portals for collecting Family History data
Description: Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
Study: NCT01900002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Yttrium Y 90 Glass Microspheres
Description: Given IA
Study: NCT00097981

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thalidomide
Description: Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOXIL
Description: DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
Study: NCT04541914

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 5-gene classification model
Description: Peripheral blood marker-based molecular diagnostic method for AMR in ABOiKT
Study: NCT00888238

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
Study: NCT00903279

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Altabax (retapamulin)
Description: Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
Study: NCT01359566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen placarbil 15 mg BID
Description: arbaclofen placarbil 15 mg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for arbaclofen placarbil 15, 30 and 45 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen placarbil 30 mg BID
Description: arbaclofen placarbil 30 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arbaclofen placarbil 45 mg BID
Description: arbaclofen placarbil 45 mg BID
Study: NCT03239509

Intervention type: PROCEDURE
Intervention: bioprosthesis implantation between 2000-2015
Description: Implantation of a bioprosthesis in aortic position with cardiopulmonary bypass

Intervention type: PROCEDURE
Intervention: mechanical prosthesis implantation between 2000-2015
Description: Implantation of a mechanical prosthesis in aortic position with cardiopulmonary bypass
Study: NCT02751398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10mg
Description: Matching placebo for dapagliflozin 10 mg
Study: NCT04019678

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Omission of Axillary dissection
Description: In Group 1 and 2: Axillary dissection won't be performed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Omission of Axillary dissection
Description: In Group 1 and 2: Axillary dissection won't be performed
Study: NCT00769041

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin
Description: 400mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 100mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: avanafil
Description: 800mg single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: single dose
Study: NCT02879877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCB7858

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02075437

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feeling and Body Investigators with Functional Abdominal Pain
Description: Investigator's ten session intervention trains children to be Feeling and Body Investigators. Half of the sessions will be done in clinic and half at home via web-camera to facilitate generalization. During the treatment child/caregiver dyads will 1) gather body clues (Learn), 2) investigate (Experience: perform interoceptive mystery missions to explore a body sensation), 3) organize body clues (Contextualize: recall other context that evoke similar sensations), and 4) go on increasingly daring missions (Challenge: decrease avoidance and safety behaviors).~If successful, young children with FAP who complete the FBI early intervention will learn to experience changes in the viscera as fun and fascinating, rather than scary, and will develop new capacities for pain management, adaptive functioning, and emotion regulation.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Strategies
Description: 1. identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis:~2. adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children;~3. incorporate caregivers as role models and facilitators based on attachment research.
Study: NCT03002779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-53718678
Description: Participants will receive a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678 corresponding to a radioactivity dose.
Study: NCT04562662

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mediVR KAGURA
Description: Approximately 20 min mediVR KAGURA-guided rehabilitation
Study: NCT03619746

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POCUS Educational Intervention
Description: Midway through the study, all Pediatric Emergency Attendings and Fellows at Jacobi Medical Center will receive an educational session that describes how to properly perform a soft tissue examination using point-of-care ultrasound to differentiate between cellulitis and local allergic reaction.
Study: NCT03743753

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The intervention is the educational session, which is a one-on-one session delivered by a research assistant using a visual aide on an iPad (power point presentation). The session is specifically tailored to the method of breast reconstruction (autologous or alloplastic) the patient will undergo and reviews the basics of their reconstruction, explains the normal in-hospital course and post-operative recovery, reviews potential complications and provides advice from previous breast reconstruction patients.
Study: NCT02441309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifamurtide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifamurtide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mifamurtide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Study: NCT03726151

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent Reminders
Description: Automated, system-generated mailed or text message reminders

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent clinic-system strategies
Description: 1. Workflow modifications to reduce missed opportunities for vaccination~2. Provider- and clinic-level audit and feedback~3. Provider \& staff training on workflow modifications and communication strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined Condition
Description: Parent reminders and multicomponent clinic-system strategies
Study: NCT01950611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Combination of arsenic trioxide with bortezomib in the treatment of relapsed acute promyelocytic leukemia
Study: NCT04350086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treatment with Dexmedetomidine
Description: Administration of Dexmedetomidine in continuous infusion by electric syringe pump at a dose of 0.4 µg / kg / h, with dose adjustment according to the sedation score and tolerance.
Study: NCT00724321

Intervention type: DRUG
Group type: OTHER
Intervention: iloprost
Description: A dose of inhaled iloprost (or placebo) will be given once at baseline and then at altitude. Measurements will be obtained before and after inhalation. Patients will then cross over and be given a dose of placebo (or iloprost)and measurements will be repeated.
Study: NCT03483064

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interferential current
Description: interferential currents of 4,000 Hz carrier frequency, 100 Hz of AMF, for 20 minutes and with an amplitude up to the motor threshold
Study: NCT03061734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Acetaminophen
Description: Naltrexone plus acetaminophen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone and Acetaminophen-High Dose
Description: Naltrexon (high dose) plus acetaminophen

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naltrexone Alone (regular dose)
Description: Naltrexone Alone plus Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen Alone
Description: Acetaminophen Alone plus Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Two Placebo capsules
Study: NCT04473170

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC)
Description: SENTAD-COVID Study intervention consists of Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy through jet nebulization in addition to standard care. The NHPBSC were characterized as CD90+, CD133+, Oct-4+ (pluripotent markers), and CD45-, CD71-, based on multiparameter flow cytometry.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COVID-19 standard care
Description: UAE National Guidelines for Clinical Management and Treatment of COVID-19.
Study: NCT02726425

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diabetes Self Management Medical Group Visits
Description: The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians \& peer leaders lasting \~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diabetes Self Management Medical Group Visits
Description: The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians \& peer leaders lasting \~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
Study: NCT00584922

Intervention type: PROCEDURE
Intervention: Endoscopy in group I (all patients)
Description: Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
Study: NCT03643978

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: The decision aids aim to inform the patients about the diagnosis and the treatment options. They aim to help the patient prioritize and make an informed decision.
Study: NCT02478957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PA101
Description: 40 mg PA101 administered via inhalation three times daily for 6 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo administered via inhalation three times daily for 6 weeks
Study: NCT02682680

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colesevelam
Description: Colesevelam 3.75 g daily for 24 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Ezetimibe 10 mg daily for 24 weeks
Study: NCT00604877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill Exercise
Description: 3 times per week for 6 months, with target of 45 minutes at 60-70% heart rate range

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Stretching/ROM
Description: 3 times per week for 6 months, passive and active stretching and range of motion (ROM) exercises for the upper and lower extremities
Study: NCT02355431

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itacitinib
Description: tablets to be administered by mouth once daily at dose selected from safety run-in phase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: 150 mg tablets administered by mouth once daily at total daily dose of 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: erlotinib
Description: 150 mg tablets administered by mouth once daily at total daily dose of 150 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
Study: NCT04347642

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical port placement
Description: The port will be inserted in the midline at the level of the umbilicus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Paraumbilical port placement
Description: The port will be inserted 3-4cm laterally to the midline at the level of the umbilicus.
Study: NCT01653353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer physician-applied recommendation to the physicians
Description: The peer physician-applied recommendation will include scientific information, practical recommendations to correctly supplement with calcium and vitamin D and a list of individual appraisals of the prescribed supplements among the residents.
Study: NCT03902496

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIT-6 Questionnaire
Description: Headache Impact Test

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: HIT-6 Questionnaire
Description: Headache Impact Test

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Avulux Spectacles
Description: Avulux™ Optical Filter in the Form of Spectacle Lenses

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Spectacles
Description: Sham
Study: NCT02683837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pupillometry
Description: Pupillary diameter measured every 5 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: Administered to maintain a Bispectral Index between 40 and 60
Study: NCT01211808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-914832
Description: Tablets, Oral, 30 mg, once, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-914832
Description: Tablets, Oral, 30 mg, once, 1 day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Tablets, Oral, 360 mg, once daily, 10 days
Study: NCT02683837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Administered to maintain a Bispectral Index between 40 and 60
Study: NCT03804762

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: the third space robotic and endoscopic cooperative surgery
Description: This technique combines the endoscopic techniques and the merits of Da Vinci surgical robot, such as flexible and precise instruments, tremors filtering system and a 3-D surgical view, and take full advantage of the methodology of the third space to dissect gastric submucosal tumors.
Study: NCT01506466

Intervention type: OTHER
Group type: OTHER
Intervention: blood test/ additional measurement
Description: blood test (hormonal, inflammatory, lipid and growth factors); body composition measurements; energy balance evaluation
Study: NCT02648386

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Laparoscopic surgery
Description: Completely resected rectal tumor.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffold transplantation
Description: After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffold/BMMCs transplantation
Description: Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve.
Study: NCT01767142

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Zeltiq System with Modified Belt Applicator
Description: Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
Study: NCT01242813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACZ885
Study: NCT03124927

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DCI pulse oximeter sensor
Study: NCT02648386

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NeuroRegen scaffold/HUC-MSCs transplantation
Description: Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.
Study: NCT02111733

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hs-TNT dosage
Description: Bloodwork before and after hemodialysis for high sensibility troponins T blood level
Study: NCT00786045

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home Cycling Program
Description: Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
Study: NCT01130129

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ex-vivo treatments with flavonoids
Description: Ex-vivo treatment of platelets with a range of flavonoids